Didier Esquieu
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Didier Esquieu.
Comptes Rendus De L Academie Des Sciences Serie Iii-sciences De La Vie-life Sciences | 2000
Jean-Marie Peloponese; Catherine Grégoire; Sandrine Opi; Didier Esquieu; James N. Sturgis; Evelyne Lebrun; Eliane F. Meurs; Yves Collette; Daniel Olive; Anne-Marie Aubertin; Myriam Witvrow; Christophe Pannecouque; Erik De Clercq; Christian Bailly; Jacques Lebreton; Erwann Loret
Tat is a viral protein essential for activation of the HIV genes and plays an important role in the HIV-induced immunodeficiency. We chemically synthesized a Tat protein (86 residues) with its six glycines C alpha labelled with 13C. This synthetic protein has the full Tat activity. Heteronuclear nuclear magnetic resonance (NMR) spectra and NOE back-calculation made possible the sequential assignment of the 86 spin systems. Consequently, 915 NMR restraints were identified and 272 of them turned out to be long range ([i-j] > 4), providing structural information on the whole Tat protein. The poor spectral dispersion of Tat NMR spectra does not allow an accurate structure to be determined as for other proteins studied by 2D NMR. Nevertheless, we were able to determine the folding for Tat protein at a 1-mM protein concentration in a 100 mM, pH 4.5 phosphate buffer. The two main Tat functional regions, the basic region and the cysteine-rich region, are well exposed to solvent while a part of the N-terminal region and the C-terminal region constitute the core of Tat Bru. The basic region adopts an extended structure while the cysteine-rich region is made up of two loops. Resolution of this structure was determinant to develop a drug design approach against Tat. The chemical synthesis of the drugs allowed the specific binding and the inhibition of Tat to be verified.
Retrovirology | 2005
Jean de Mareuil; Manon Carré; Pascale Barbier; Grant R. Campbell; Sophie Lancelot; Sandrine Opi; Didier Esquieu; Jennifer Watkins; Charles Prevôt; Diane Braguer; Vincent Peyrot; Erwann Loret
BackgroundHIV infection and progression to AIDS is characterized by the depletion of T cells, which could be due, in part, to apoptosis mediated by the extra-cellular HIV-encoded Tat protein as a consequence of Tat binding to tubulin. Microtubules are tubulin polymers that are essential for cell structure and division. Molecules that target microtubules induce apoptosis and are potent anti-cancer drugs. We studied the effect on tubulin polymerization of three Tat variants: Tat HxB2 and Tat Eli from patients who are rapid progressors (RP) and Tat Oyi from highly exposed but persistently seronegative (HEPS) patients. We compared the effect on tubulin polymerization of these Tat variants and peptides corresponding to different parts of the Tat sequence, with paclitaxel, an anti-cancer drug that targets microtubules.ResultsWe show that Tat, and specifically, residues 38–72, directly enhance tubulin polymerization. We demonstrate that Tat could also directly trigger the mitochondrial pathway to induce T cell apoptosis, as shown in vitro by the release of cytochrome c from isolated mitochondria.ConclusionsThese results show that Tat directly acts on microtubule polymerization and provide insights into the mechanism of T cell apoptosis mediated by extra-cellular Tat.
Journal of Biological Chemistry | 2005
Grant R. Campbell; Jennifer Watkins; Didier Esquieu; Eddy Pasquier; Erwann Loret; Stephen A. Spector
HIV infection and the progression to AIDS are characterized by the depletion of CD4+ T cells through apoptosis of the uninfected bystander cells and the direct killing of HIV-infected cells. This is mediated in part by the human immunodeficiency virus, type 1 Tat protein, which is secreted by virally infected cells and taken up by uninfected cells and CD178 gene expression, which is critically involved in T cell apoptosis. The differing ability of HIV strains to induce death of infected and uninfected cells may play a role in the clinical and biological differences displayed by HIV strains. We chemically synthesized the 86-residue truncated short variant of Tat and its full-length form. We show that the trans-activation ability of Tat at the long terminal repeat does not correlate with T cell apoptosis but that the ability of Tat to up-regulate CD178 mRNA expression and induce apoptosis in T cells is critically dependent on the C terminus of Tat. Moreover, the greater 86-residue Tat-induced apoptosis is via the extrinsic pathway of CD95-CD178.
Retrovirology | 2006
Jennifer Watkins; Sophie Lancelot; Grant R. Campbell; Didier Esquieu; Jean de Mareuil; Sandrine Opi; Sylvie Annappa; Jean-Pierre Salles; Erwann Loret
BackgroundExtra-cellular roles of Tat might be the main cause of maintenance of HIV-1 infected CD4 T cells or reservoir cells. We developed a synthetic vaccine based on a Tat variant of 101 residues called Tat Oyi, which was identified in HIV infected patients in Africa who did not progress to AIDS. We compared, using rabbits, different adjuvants authorized for human use to test on ELISA the recognition of Tat variants from the five main HIV-1 subtypes. A formulation was tested on macaques followed by a SHIV challenge with a European strain.ResultsTat Oyi with Montanide or Calcium Phosphate gave rabbit sera able to recognize all Tat variants. Five on seven Tat Oyi vaccinated macaques showed a better control of viremia compared to control macaques and an increase of CD8 T cells was observed only on Tat Oyi vaccinated macaques. Reservoir cells were not detectable at 56 days post-challenge in all Tat Oyi vaccinated macaques but not in the controls.ConclusionThe Tat Oyi vaccine should be efficient worldwide. No toxicity was observed on rabbits and macaques. We show in vivo that antibodies against Tat could restore the cellular immunity and make it possible the elimination of reservoir cells.
Spectroscopy | 2003
Didier Esquieu; Jean-Marie Peloponese; Sandrine Opi; Catherine Grégoire; Jean de Mareuil; Jennifer Watkins; Grant R. Campbell; Jean-Pierre Dunot; James N. Sturgis; Myriam Witvrouw; Christophe Pannecouque; Erik De Clercq; Mickaël Montembault; Vo-Thanh Giang; Monique Villiéras; Valérie Fargeas; Jacques Lebreton; Erwann Loret
Tat is a regulatory HIV-1 protein, which has the particularity to be secreted very early by HIV-infected cells. The extra cellular roles of Tat are suspected to be the main cause of the maintenance of reservoirs of HIV-infected cells and the failure of actual AIDS therapies to eradicate HIV. This study describes the rationale used to design molecules that bind to a target area containing an hydrophobic pocket identified in the 2D-NMR structure of Tat. Molecules were synthesized and the derivative named TDS2 was shown to be a Tat inhibitor. Fluorescence revealed that TDS2 binds in the target area, which is conserved across five different Tat variants representative of the main HIV-1 subtypes. TDS2 inhibited in vitro HIV-1 replication in human T-cells. Further chemical modifications remain necessary to enhance affinity to Tat and reduce cytotoxicity.
Journal of Biological Chemistry | 2004
Grant R. Campbell; Eddy Pasquier; Jennifer Watkins; Véronique Bourgarel-Rey; Vincent Peyrot; Didier Esquieu; Pascale Barbier; Jean de Mareuil; Diane Braguer; Pontiano Kaleebu; David Yirrell; Erwann Loret
Journal of Biological Chemistry | 2002
Sandrine Opi; Jean-Marie Peloponese; Didier Esquieu; Grant R. Campbell; Jean de Mareuil; Anne Walburger; Catherine Grégoire; Emmanuelle Bouveret; David Yirrell; Erwann Loret
Biopolymers | 2001
Catherine Grégoire; Jean-Marie Peloponese; Didier Esquieu; Sandrine Opi; Grant R. Campbell; Evelyne Lebrun; Jacques Lebreton; Erwann Loret
Biochemistry | 2007
Alexander A. Makarov; Philipp O. Tsvetkov; Claude Villard; Didier Esquieu; Bertrand Pourroy; Jacques Fahy; Diane Braguer; Vincent Peyrot; Daniel Lafitte
Vaccine | 2004
Sandrine Opi; Jean-Marie Peloponese; Didier Esquieu; Jennifer Watkins; Grant R. Campbell; Jean de Mareuil; Kuan Teh Jeang; David Yirrell; Pontiano Kaleebu; Erwann Loret